Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.

Memorias do Instituto Oswaldo Cruz - 1 Jan 2022

El-Jaick Kenia Balbi, Ribeiro-Alves Marcelo, Soares Marcos Vinícius Guimarães, Araujo Gabriela Eduardo França de, Pereira Gabriel Rodrigues Coutinho, Rolla Valeria Cavalcanti, Mesquita Joelma Freire De, De Castro Liane

Abstract excerpt

BACKGROUND: Distinct N-acetyltransferase 2 (NAT2) slow acetylators genotypes have been associated with a higher risk to develop anti-tuberculosis drug-induced hepatotoxicity (DIH). However, studies have not pointed the relevance of different acetylation phenotypes presented by homozygotes and compound heterozygotes slow acetylators on a clinical basis. OBJECTIVES: This study aimed to investigate the association...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetyltransferases
Share to Antitubercular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Chemical and Drug Induced Liver Injury

Share to Genotype

Share to Homozygote

Share to Tuberculosis

Source

Open in PubMed Open full text

Identifiers

PMID: 35588539
DOI: 10.1590/0074-02760210328
PMCID: PMC9049236

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.PMID 35588539Read ↗

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in Mexican patients: From genotype to molecular structure characterization.Semantic proximity Read ↗

NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.Semantic proximity Read ↗

N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.Semantic proximity Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.Semantic proximity Read ↗

NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.Semantic proximity Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.Semantic proximity Read ↗

tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity.Semantic proximity Read ↗

NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity.Semantic proximity Read ↗

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.